Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PFSA vs FGL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FGL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–3 Matrix Metrics)

FGL Overall Winner 6-Pillar Tally: PFSA 1 – 4 FGL (1 Tie) Matrix Metrics: PFSA 3 – 4 FGL

As of Nov 16, 2026, Founder Group Limited Class A (FGL) is the stronger overall head-to-head candidate over Profusa, Inc. (PFSA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PFSA carries a Unified Composite Score of 45.9/100 (HOLD) at $0.41 (N/M Forward P/E, 0.0% operating margin), whereas FGL carries 52.7/100 (HOLD) at $0.93 (N/M Forward P/E, 0.4% operating margin).

  • Technical & Structure Timing Caution: PFSA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.6); meanwhile FGL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PFSA vs FGL
PFSA NASDAQ
Profusa, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.41
-7.63% 1D
Market Cap $278,597
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -10.74β · 120% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -55.2%), weak momentum, RSI 38
RSI-14: 37.6 · SMA20: $0.67 · SMA50: $1.38
FGL NASDAQ Head-to-Head Winner
Founder Group Limited Class A Ordinary Shares
Construction - Special Trade Contractors
$0.93
-3.37% 1D
Market Cap $83,113
TTM Revenue $148M
Forward P/E N/M
Beta / 30D Vol -54.37β · 210% Vol
Unified Composite Score
52.7 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.7%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $1.54 · SMA50: $3.33

6-Pillar Scorecard Institutional Category Breakdown (PFSA 1 – 4 FGL)

Columns: Metric · PFSA · FGL
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale FGL
Revenue Growth (YoY) +0.0% +49.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $148M
Market Cap $278,597 $83,113
3. Profitability & Quality FGL
Gross Margin N/A 11.3%
Operating Margin 0.0% 0.4%
Net Profit Margin 0.0% -3.4%
Return on Equity (ROE) 0.0% -16.7%
4. Balance Sheet & Cash Flow FGL
Cash Generation (TTM) N/A $2.8M EBITDA
Cash Flow Margin N/A 1.9% EBITDA Mgn
Net Cash / Leverage 0.0% ROE $12.87 Book/Sh · -16.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PFSA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat FGL
OpEx & R&D Intensity N/A 10.9% of Rev ($16M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Engineering & Construction Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PFSA (3) vs FGL (4)
Institutional Metric PFSA FGL Criterion Row Edge
Market Capitalization
Scale
$278,597 $83,113 Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +49.7% Higher Growth FGL
Operating Margin (TTM)
Profitability
0.0% 0.4% Higher Margin FGL
Net Profit Margin
Profitability
0.0% -3.4% Higher Margin PFSA
Return on Equity (ROE)
Capital Efficiency
0.0% -16.7% Higher ROE PFSA
52-Week Range Position
Momentum
1% ($0–$28) 3% ($0–$32) Stronger Trend FGL
Beta / 30D Volatility
Risk Regime
-10.74β · 120% Vol -54.37β · 210% Vol Lower Realized Risk PFSA
Unified Institutional Score
Composite Signal
45.9 / 100 (HOLD) 52.7 / 100 (HOLD) Higher Composite FGL
Trailing 12M Revenue (USD)
Operating Scale
N/A $148M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 11.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (0.0% ROE) $2.8M EBITDA ($12.87 Book/Sh · -16.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PFSA +14.13 pp
PFSA: -55.56% · FGL: -69.69%
3M Horizon FGL +241.19 pp
PFSA: -98.49% · FGL: +142.7%
6M Horizon PFSA +44.68 pp
PFSA: -5.18% · FGL: -49.86%
1Y Horizon FGL +64.69 pp
PFSA: +112.21% · FGL: +176.9%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PFSA vs FGL. Trailing 12-month operating profitability (PFSA 0.0% vs FGL 0.4%) and valuation multiples (PFSA N/M vs FGL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PFSA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M
FGL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$148M
Gross Margin11.3%
Op. Margin0.4%
ROE / Fwd P/E-16.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PFSA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PFSA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FGL BREAKDOWN
53d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PFSA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $278,597 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FGL Moat Profile Cyclical / Execution-Driven Positioning
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $83,113 market capitalization and 0.4% operating margin.
OpEx & R&D Reinvestment 10.9% of Rev ($16M)
90D Engineering Disclosures 0 Published

Investor FAQ PFSA vs FGL Key Questions & Quantitative Answers

As of Nov 16, 2026, Founder Group Limited Class A (FGL) is the stronger overall head-to-head candidate over Profusa, Inc. (PFSA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PFSA carries a Unified Composite Score of 45.9/100 (HOLD) at $0.41 (N/M Forward P/E, 0.0% operating margin), whereas FGL carries 52.7/100 (HOLD) at $0.93 (N/M Forward P/E, 0.4% operating margin). Technical & Structure Timing Caution: PFSA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.6); meanwhile FGL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FGL leads the Growth & Scale pillar: PFSA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FGL at +49.7% YoY revenue growth and +0.0% YoY earnings growth on $148M TTM revenue (11.3% gross margin, 0.4% operating margin). On trailing 12-month operating scale, PFSA generates N/A in USD-normalized revenue versus $148M for FGL. In operating R&D and SG&A reinvestment, PFSA deploys N/A (0 90-day corporate R&D disclosures) versus 10.9% of Rev ($16M) (0 disclosures) for FGL.

PFSA and FGL trade at balanced relative valuation multiples. PFSA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FGL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (1.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PFSA (0.0% ROE) versus FGL (-16.7% ROE) capital efficiency.

In options market volatility and institutional positioning, PFSA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-10.74β · 120% Vol realized risk). By comparison, FGL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-54.37β · 210% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.